By Josee Rose

AstraZeneca PLC (AZN) on Tuesday said the U.S. Food and Drug Administration has accepted a supplemental biologics license application for Imfinzi, granting the drug Priority Review status.

Imfinzi is being developed to treat patients with stage 3 unresectable non-small cell lung cancer whose disease hasn't progressed after some chemoradiation therapy.

Imfinzi has had positive data from a phase 3 trial, which continues to evaluate overall survival, one of its primary endpoints.

Write to Josee Rose at josee.rose@wsj.com.

(END) Dow Jones Newswires

October 17, 2017 02:46 ET (06:46 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024 Click aqui para mais gráficos Astrazeneca.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024 Click aqui para mais gráficos Astrazeneca.